At Boehringer, Adams would have searched vast libraries of compounds to find possible drugs.
Adams invented Viramune, an AIDS drug, while working at Boehringer Ingleheim , the German pharmaceutical firm.
Pradaxa, from Boehringer Ingelheim, was approved by the Food and Drug Administration last October.
Germany's Boehringer Ingelheim GmbH was also working on a CGRP antagonist but canceled development.
Novartis, Abbott Laboratories and Boehringer Ingelheim are all thought to be pursuing hedgehog programs.
Boehringer, in developing linagliptin, is taking another biochemical approach to the same medical ends.
FORBES: Diabetes Market Booms As Substitutes Sought For Daily Insulin Dosing
In January 2011, Lilly entered into a deal with privately-held Boehringer to market linagliptin.
FORBES: Diabetes Market Booms As Substitutes Sought For Daily Insulin Dosing
The first of these warfarin replacements, from Boehringer Ingelheim, goes before an FDA advisory committee on Monday.
Adams left Merck in 1987 to make a name for himself at the German drug firm Boehringer Ingelheim.
Boehringer Ingelheim is starting to inform physicians about a new contraindication for its oral anticoagulant drug Pradaxa (dabigatran).
FORBES: Pradaxa To Be Contraindicated In Patients With Mechanical Heart Valves
This could force Boehringer to market Pradaxa as equivalent to warfarin, not better.
This month Vertex plans to present initial efficacy results for a drug it believes will avoid the toxicity problems of Boehringer's compound.
More recently a German firm, Boehringer Ingelheim, has developed its own diabetes treatment, linagliptin, with the trade name Tradjenta.
FORBES: Diabetes Market Booms As Substitutes Sought For Daily Insulin Dosing
Dr. Hirth, at the time a 40-year-old research manager at Boehringer Mannheim, was intrigued by this concept, but his employer had little interest.
Its manufacturer, Boehringer Ingelheim, must now show it is safe and effective, despite recent reassurances from the World Health Organisation that it can be used.
In January 2010, Lilly formed a new diabetes-drug partnership with Boehringer Ingelhiem GmbH, prompting Amylin to file a lawsuit alleging breach of its own contract with Lilly.
WSJ: FDA Approves Amylin's Bydureon Diabetes Drug After Delays
For more solutions from health social entrepreneurs around the world, explore Transforming Health Systems: Gamechanging Business Models, a new online competition launched in partnership with Boehringer Ingelheim.
FORBES: Disruptive Innovation: A Prescription For Better Health Care
My own best guess is that Eli Lilly, Amylin, and Boehringer will work out their differences in a manner that will allow them to continue doing business in something akin to their marketing arrangements now in place.
FORBES: Diabetes Market Booms As Substitutes Sought For Daily Insulin Dosing
The main point of the article is to explain why FDA is not taking action against Spiriva (generic name: tiotropium), a treatment for chronic obstructive pulmonary disorder sold by Boehringer Ingelheim and Pfizer, despite a meta-analysis that raised concerns.
Amylin went to court last year to end a development and marketing deal with Eli Lilly for both Bydureon and Byetta, ending a tumultuous partnership that finally unraveled when Lilly signed a rival deal with Boehringer Ingelheim, which infuriated Amylin executives.
FORBES: And They're Off: Amylin And Novo Nordisk Begin Their Battle
The split ends a decades-long partnership that appeared to unravel after Lilly signed a deal earlier this year with Boehringer Ingelheim to jointly develop and sell several diabetes compounds that are in mid- and late-stage development, including a Boehringer oral diabetes agent known as linagliptin.
Given the circumstances, the split is not surprising, since Lilly began devoting two-thirds of its sales force to promote the DPP-4 that was developed with Boehringer and was recently approved by the FDA. Keep in mind that the drug is targeted at the same patient who would use Byetta.
The first clear hint of targeted therapy's potential came in late 2003, when researchers at the German firm Boehringer Ingelheim reported that its hepatitis C protease inhibitor lowered the quantity of virus particles by roughly 99.9% in eight patients in two days of treatment, beating what interferon can accomplish in that time period.
Through this multi-year collaboration the partners are launching fifty leading Ashoka social entrepreneurs across the world, combining the creativity and knowledge of both partners to envision the future of the health arena, spotting and launching hundreds of promising young health change makers, giving 25 Boehringer Ingelheim executives 6-month opportunities to work in the organizations of top heath social entrepreneurs.
FORBES: Three Ways to Secure Your Social License to Operate in 2013
应用推荐